What does the Phase III trial data show?
The best evidence for GLP-1 efficacy comes from large, placebo-controlled Phase III trials conducted by the manufacturers of branded GLP-1 products. These trials are not small studies — STEP 1 (semaglutide) enrolled 1,961 participants and SURMOUNT-1 (tirzepatide) enrolled 2,539 participants. Both ran for approximately 68–72 weeks.
The headline results:
- Semaglutide 2.4 mg weekly (STEP 1): Mean body weight reduction of 14.9% vs. 2.4% for placebo. 86% of participants achieved at least 5% weight loss (vs. 32% for placebo). 50% achieved at least 15% weight loss.
- Tirzepatide 15 mg weekly (SURMOUNT-1): Mean body weight reduction of 20.9% vs. 3.1% for placebo. 91% of participants achieved at least 5% weight loss. 57% achieved at least 20% weight loss.
These are mean results from well-designed trials. Your individual result depends on factors including your baseline metabolic status, dose tolerance, protein intake, and how long you stay on the protocol.
| Metric | Semaglutide 2.4 mg/wk (STEP 1) | Tirzepatide 15 mg/wk (SURMOUNT-1) |
|---|---|---|
| Trial duration | 68 weeks | 72 weeks |
| Participants | 1,961 | 2,539 |
| Mean weight reduction | 14.9% | 20.9% |
| Achieved ≥5% weight loss | 86% | 91% |
| Achieved ≥15% weight loss | 50% | 63% |
| Receptor mechanism | GLP-1 agonist | Dual GIP + GLP-1 agonist |
How does GLP-1 work to reduce body weight?
GLP-1 (glucagon-like peptide-1) is a hormone secreted by the gut in response to food intake. It signals the pancreas to release insulin in a glucose-dependent manner and signals the brain — primarily the hypothalamic arcuate nucleus — to reduce appetite and increase satiety.
GLP-1 receptor agonists are synthetic versions of this hormone, engineered for a much longer half-life than the body’s own GLP-1 (which clears in minutes). Semaglutide has a half-life of approximately one week, enabling once-weekly dosing.
The appetite-suppressing effect operates through multiple pathways:
- Central appetite suppression: Hypothalamic GLP-1 receptors reduce hunger signals and increase satiety signals, often described by patients as “food noise” quieting.
- Gastric emptying delay: Food moves more slowly out of the stomach, extending the post-meal satiety period and reducing caloric intake at subsequent meals.
- Reward pathway modulation: Emerging research suggests GLP-1 receptors in the mesolimbic system may reduce the reward salience of food (and potentially other rewarding behaviors), contributing to the broad appetite reduction patients report.
Tirzepatide adds GIP (glucose-dependent insulinotropic polypeptide) receptor agonism to this mix. GIP receptors in adipose tissue and the central nervous system appear to work synergistically with GLP-1 receptor stimulation, potentially explaining tirzepatide’s larger effect sizes at higher doses.
Who responds best to GLP-1 therapy?
While the mean results from clinical trials are impressive, understanding where you fall in the distribution matters. Research and clinical experience point to several factors associated with stronger response:
- Higher baseline BMI: Patients with a higher starting BMI tend to achieve larger absolute weight reductions, though percentage reductions can be comparable.
- Adequate protein intake: Patients who maintain sufficient protein intake while in caloric deficit preserve more lean mass and tend to sustain weight loss better. GLP-1 therapy without protein attention can lead to muscle mass loss alongside fat loss.
- Reaching therapeutic dose: Many suboptimal outcomes trace to tolerability-limited titration. Patients who cannot reach higher doses due to side effects achieve smaller weight reductions. Slower titration protocols that preserve tolerability often produce better long-term outcomes than fast titration that causes discontinuation.
- Duration of treatment: Weight loss with GLP-1 therapy is progressive. Patients who discontinue at 8 weeks haven’t allowed the medication to reach its full effect.
Non-responders: how common and why?
Approximately 10–15% of trial participants are classified as non-responders to GLP-1 therapy (less than 5% body weight reduction). Contributing factors include genetic variation in GLP-1 receptor sensitivity, subtherapeutic dosing due to tolerability issues, and offsetting behaviors (increased caloric compensation). Genuinely refractory non-response to adequately dosed GLP-1 therapy is less common than the narrative around “GLP-1 not working” would suggest.
What happens when you stop GLP-1 therapy?
This is among the most important honest answers the field can give: most patients regain a significant portion of lost weight after discontinuing GLP-1 therapy without lifestyle infrastructure in place. The STEP 4 withdrawal trial demonstrated that participants who stopped semaglutide after 20 weeks regained approximately two-thirds of their lost weight within a year.
This is not evidence that GLP-1 “doesn’t work.” It reflects the reality that obesity has biological drivers that the medication suppresses while active. Framing GLP-1 as a long-term management tool (as with many chronic condition medications) rather than a short-term intervention is more aligned with what the data shows.
Patients who build sustainable dietary habits — especially adequate protein intake and structured eating patterns — during their protocol period tend to regain less weight after discontinuation than those who rely exclusively on the appetite suppression without restructuring how they eat.
Compounded GLP-1: what is available and how does it differ?
Branded GLP-1 medications have faced significant access and cost barriers. During FDA-documented supply shortages, licensed 503A compounding pharmacies have been permitted to compound semaglutide and tirzepatide as patient-specific preparations.
Compounded semaglutide and tirzepatide are patient-specific preparations compounded by licensed 503A pharmacies. They are not manufactured by the branded drug’s maker, are not FDA-approved as finished drug products, and are governed by USP compounding standards rather than the branded drug approval pathway.
PepScribe’s compounded semaglutide and tirzepatide are sourced from licensed 503A pharmacies in the USA. No hidden overseas supply chain.
Access to compounded GLP-1 therapy requires a valid clinician-patient relationship and a prescription. It is not available over the counter, through third-party sites without a prescriber, or as a supplement.
Frequently asked questions
Does GLP-1 work for weight loss?
Yes. GLP-1 receptor agonists like semaglutide and tirzepatide are the most effective pharmacological tools available for weight management in adults with obesity or overweight. Phase III clinical trials have demonstrated 15–22% mean body weight reduction over 68–72 weeks. Results are dose-dependent, and individual variation is real.
How does GLP-1 work to reduce body weight?
GLP-1 receptor agonists act on GLP-1 receptors in the hypothalamus to reduce appetite and increase satiety signals. They also slow gastric emptying, reduce caloric intake, and — in the case of tirzepatide — additionally act on GIP receptors to improve insulin sensitivity and energy expenditure. The net effect is a substantial reduction in caloric intake over time.
How long does it take for GLP-1 to work?
Appetite suppression typically begins within the first 1–2 weeks of treatment. Meaningful weight changes are usually visible by weeks 4–8. Peak weight loss outcomes in clinical trials were observed at 68–72 weeks of continuous treatment. Results require sustained use — most weight returns if the medication is stopped without lifestyle interventions in place.
Does GLP-1 work for everyone?
Most patients on clinician-supervised GLP-1 protocols achieve meaningful weight reduction, but there is genuine individual variation. Genetic differences in GLP-1 receptor expression, baseline metabolic health, adherence to nutritional protein targets, and the degree of dose titration all influence results. About 10–15% of patients in trials are classified as non-responders, though many of these cases involve subtherapeutic dosing or tolerability limitations.
What is the difference between semaglutide and tirzepatide?
Semaglutide is a GLP-1 receptor agonist only. Tirzepatide is a dual GIP/GLP-1 receptor agonist. In head-to-head data and indirect comparisons, tirzepatide at higher doses tends to produce greater weight reduction. The right choice depends on individual clinical factors, and your prescribing clinician should guide the selection.